



BRCA1 and BRCA2 Genetic Testing

Purpose

This policy is intended to ensure correct provider reimbursement and serves only as a general resource regarding Molina Healthcare’s reimbursement policy for the services described in this policy. It is not intended to address every aspect of a reimbursement situation, nor is it intended to impact care decisions. This policy was developed using nationally accepted industry standards and coding principles. In a conflict, federal and state guidelines, as applicable, and the member’s benefit plan document supersede the information in this policy. Also, to the extent of conflicts between this policy and the provider contract language, the Provider contract language will prevail. Coverage may be mandated by applicable legal requirements of a State, the Federal government or the Centers for Medicare and Medicaid Services (CMS). References included were accurate at the time of policy approval. If there is a state exception, please refer to the state exception table listed below.

Policy Overview

The BRCA gene test is an examination that uses DNA (Detection by Nucleic Acid) analysis to identify harmful mutations in two breast cancer susceptibility genes: BRCA1 (Breast Cancer gene 1) and BRCA2 (Breast Cancer gene 2).

When assigning CPT (Current Procedural Terminology) codes for BRCA1 and BRCA2 testing, it is important to ensure that the diagnosis codes align with the medical necessity criteria. Molina Healthcare recommends reviewing the reference materials provided to identify the appropriate diagnosis codes for an accurate assessment of medical necessity.

Reimbursement Guidelines

Molina Healthcare covers BRCA1 and BRCA2 Genetic testing only when relevant signs, symptoms, or diseases are diagnosed. To request reimbursement for BRCA1 and BRCA2 Genetic Testing, it is essential to include the appropriate diagnosis codes. Incorrect submissions of diagnosis and procedure codes may result in Molina Healthcare reviewing, denying, and recovering any incorrectly paid claims.

Supplemental Information

Definitions

Term	Definition
BRCA1	Breast Cancer Gene 1
BRCA2	Breast Cancer Gene 2
CMS	Center for Medicare and Medicaid
CPT	Current Procedural Terminology
DNA	Deoxyribonucleic Acid - a self-replicating material that is present in nearly all living organisms as the main constituent of chromosomes and is the carrier of genetic information

State Exceptions

State	Exception
-------	-----------

Documentation History

Type	Date	Action
Published		
Revised Date		

References

This policy was developed using.

- CMS
- State Medicaid Regulatory Guidance
- State Contracts

Agency:	Document description	Reference links:
CMS	Billing and Coding: BRCA1 and BRCA2 Genetic Testing	Article - Billing and Coding: BRCA1 and BRCA2 Genetic Testing (A57449) (cms.gov)
CMS	Billing and Coding: BRCA1 and BRCA2 Genetic Testing	Article - Billing and Coding: BRCA1 and BRCA2 Genetic Testing (A56542) (cms.gov)
CMS	Billing and Coding: MoIDX: BRCA1 and BRCA2 Genetic Testing	Article - Billing and Coding: MoIDX: BRCA1 and BRCA2 Genetic Testing (A57354) (cms.gov)
MA	Guidelines for Medical Necessity Determination for Genetic Testing for BRCA-related Breast and/or Ovarian Cancer	https://www.mass.gov/doc/genetic-testing-for-hereditary-breast-and-or-ovarian-cancer-0/download
WA	Physician-Related Services/Health Care Professional Services Pg. 355	https://www.hca.wa.gov/assets/billers-and-providers/Physician-related-serv-bg-20210701.pdf
MI	Billing and Coding: BRCA1 and BRCA2 Genetic Testing L39040 A58756	MoIDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer Billing and Coding: MoIDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer